© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Eton Pharmaceuticals, Inc. (ETON) stock surged +4.36%, trading at $30.16 on NASDAQ, up from the previous close of $28.90. The stock opened at $29.02, fluctuating between $28.93 and $31.12 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 04, 2026 | 28.93 | 31.12 | 28.93 | 30.16 | 642.55K |
| Apr 30, 2026 | 23.77 | 24.28 | 23.33 | 24.12 | 203.17K |
| Apr 29, 2026 | 23.97 | 24.11 | 23.45 | 23.58 | 184.68K |
| Apr 28, 2026 | 23.77 | 24.17 | 23.60 | 24.16 | 230.38K |
| Apr 27, 2026 | 23.00 | 23.93 | 22.54 | 23.45 | 253.58K |
| Apr 23, 2026 | 23.68 | 23.69 | 22.94 | 22.97 | 231.42K |
| Apr 22, 2026 | 23.57 | 24.00 | 23.40 | 23.61 | 214.22K |
| Apr 21, 2026 | 25.11 | 25.11 | 23.33 | 23.54 | 404.34K |
| Apr 20, 2026 | 24.86 | 25.71 | 24.60 | 25.28 | 293.58K |
| Apr 17, 2026 | 24.81 | 25.06 | 24.33 | 25.04 | 275.44K |
| Apr 16, 2026 | 26.04 | 26.23 | 24.19 | 24.43 | 734.55K |
| Apr 14, 2026 | 26.05 | 27.14 | 26.05 | 27.12 | 269.11K |
| Apr 13, 2026 | 26.00 | 26.58 | 25.34 | 26.05 | 608.54K |
| Apr 10, 2026 | 27.09 | 27.11 | 26.04 | 26.36 | 393.7K |
| Apr 09, 2026 | 26.37 | 27.19 | 26.25 | 27.10 | 332.97K |
| Apr 08, 2026 | 25.31 | 26.81 | 24.89 | 26.40 | 451.16K |
| Apr 07, 2026 | 25.00 | 25.25 | 24.66 | 25.06 | 331.1K |
| Apr 06, 2026 | 25.00 | 25.59 | 24.56 | 25.00 | 325.4K |
| Apr 02, 2026 | 25.00 | 25.56 | 24.12 | 24.99 | 472.29K |
| Apr 01, 2026 | 25.06 | 25.99 | 24.53 | 25.36 | 723.69K |
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
| Employees | 31 |
| Beta | 0.97 |
| Sales or Revenue | $21.25M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |